Loading the section…

NBP: financial statements from SEC — TradeAlmanac

NBP

NovaBridge Biosciences: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024	31/12/2023	31/12/2022
Revenue	—	—	632,000	−2M
Research and development	63M	22M	21M	23M
Selling, general and administrative	31M	30M	28M	29M
Operating expenses	94M	51M	73M	52M
Operating income	−94M	−51M	−72M	−53M
Pre-tax income	−88M	−50M	−82M	−141M
Income tax	—	0	0	103,000
Net income	−46M	−22M	−208M	−371M
Earnings per share	−0.21	−0.12	−1.09	−1.96
Earnings per share, diluted	−0.21	−0.12	−1.09	−1.96
Weighted average shares	220M	187M	191M	190M
Weighted average shares, diluted	220M	187M	191M	190M

Balance sheet

Metric	19/08/2026	18/08/2026	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021
Cash and equivalents	—	—	211M	68M	292M	343M	553M
Short-term investments	—	—	210,000

Cash flow

Metric	31/12/2025	31/12/2024	31/12/2023	31/12/2022
Operating cash flow	−21M	−53M	−73M	−50M
Depreciation and amortisation	68,000	261,000	475,000	206,000
Share-based compensation	6M	−2M	10M	13M
Capital expenditure

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator